Dr. Chanan-Khan on Ibrutinib as Backbone of Treatment for CLL

Asher A. Chanan-Khan, MD
Published: Tuesday, Aug 25, 2015



Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Mayo Clinic in Florida, discusses ibrutinib as a backbone of treatment for patients with chronic lymphocytic leukemia (CLL).

It is critical for patients with relapsed CLL to have ibrutinib as the backbone of their treatment plan and in the management of their disease, Chanan-Khan explains. Ibrutinib is found to be effective because it improves progression-free and overall survival.

In a recent study examining the combination of ibrutinib with bendamustine and ritxuimab in patients with CLL and SLL, no safety concerns were observed. Therefore, ibrutinib can be seen as a well-tolerated and safe agent for patients, Chanan-Khan adds.

SELECTED
LANGUAGE


Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Mayo Clinic in Florida, discusses ibrutinib as a backbone of treatment for patients with chronic lymphocytic leukemia (CLL).

It is critical for patients with relapsed CLL to have ibrutinib as the backbone of their treatment plan and in the management of their disease, Chanan-Khan explains. Ibrutinib is found to be effective because it improves progression-free and overall survival.

In a recent study examining the combination of ibrutinib with bendamustine and ritxuimab in patients with CLL and SLL, no safety concerns were observed. Therefore, ibrutinib can be seen as a well-tolerated and safe agent for patients, Chanan-Khan adds.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x